Blood biomarker shows ‘great promise’ predicting progression to Alzheimer’s disease in at-risk population

September 1, 2023

Neuroscience researchers at Wayne State University published a review article that confirms the usefulness of neurofilament light (NfL) blood levels to predict the likelihood and rate of progression of neurodegeneration in Alzheimer’s disease. The review article, “The Potential of Blood Neurofilament Light as a Marker of Neurodegeneration in Alzheimer’s disease,” is published in the journal Brain.

Modeling the potential of kidney disease with an integrated organoid omics map
Kidney organoids provide a promising platform in vitro to model the mechanisms of kidney disease, however, they are limited by an existing lack of knowledge of their inherent functional protein expression. In a new report in Nature Communications, Martiz Lassé and a team of scientists in medicine and kidney health, in Denmark, Germany, and the U.S., defined the organoid proteome and their transcriptome trajectories during culture, and upon exposure to the tumor necrosis factor alpha (TNFα); a cytokine stressor.
New perspectives on understanding, preventing and treating vascular dementia
Dementia is a group of brain diseases that share similar symptoms, such as memory, language, orientation, and behavioral issues. Vascular dementia generally develops in the elderly, affecting between 1% and 4% of people over the age of 65, according to Alzheimer's Switzerland. It is caused by vascular lesions that disrupt the blood supply to the brain, leading to the death of neurons.
New study shows 1 in 3 men worldwide are infected with genital human papillomavirus
A new study has been published in The Lancet Global Health showing that almost one in three men over the age of 15 are infected with at least one genital human papillomavirus (HPV) type, and one in five are infected with one or more of what are known as high risk, or oncogenic, HPV types.
First-in-class targeted microRNA therapy slows cancer tumor growth
A new cancer therapy developed by Purdue University researchers attacks tumors by tricking cancer cells into absorbing a snippet of RNA that naturally blocks cell division. As reported in Oncogene, tumors treated with the new therapy did not increase in size over the course of a 21-day study, while untreated tumors tripled in size over the same time period. The paper is tiled "A first-in-class fully modified version of miR-34a with outstanding stability, activity, and anti-tumor efficacy."
A low-cost, eco-friendly COVID test
The availability of rapid, accessible testing was integral to overcoming the worst surges of the COVID-19 pandemic, and will be necessary to keep up with emerging variants. However, these tests come with unfortunate costs.

Blood biomarker shows ‘great promise’ predicting progression to Alzheimer’s disease in at-risk population

Recent Posts

JUST IN